Recent advances in the application of metabolomics to Alzheimer's Disease

Eugenia Trushina, Michelle M. Mielke

Research output: Contribution to journalArticle

Abstract

The pathophysiological changes associated with Alzheimer's Disease (AD) begin decades before the emergence of clinical symptoms. Understanding the early mechanisms associated with AD pathology is, therefore, especially important for identifying disease-modifying therapeutic targets. While the majority of AD clinical trials to date have focused on anti-amyloid-beta (Aβ) treatments, other therapeutic approaches may be necessary. The ability to monitor changes in cellular networks that include both Aβ and non-Aβ pathways is essential to advance our understanding of the etiopathogenesis of AD and subsequent development of cognitive symptoms and dementia. Metabolomics is a powerful tool that detects perturbations in the metabolome, a pool of metabolites that reflects changes downstream of genomic, transcriptomic and proteomic fluctuations, and represents an accurate biochemical profile of the organism in health and disease. The application of metabolomics could help to identify biomarkers for early AD diagnosis, to discover novel therapeutic targets, and to monitor therapeutic response and disease progression. Moreover, given the considerable parallel between mouse and human metabolism, the use of metabolomics provides ready translation of animal research into human studies for accelerated drug design. In this review, we will summarize current progress in the application of metabolomics in both animal models and in humans to further understanding of the mechanisms involved in AD pathogenesis. This article is part of a Special Issue entitled: Misfolded Proteins, Mitochondrial Dysfunction, and Neurodegenerative Diseases.

Original languageEnglish (US)
Pages (from-to)1232-1239
Number of pages8
JournalBiochimica et Biophysica Acta - Molecular Basis of Disease
Volume1842
Issue number8
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Metabolomics
Alzheimer Disease
Mitochondrial Diseases
Neurobehavioral Manifestations
Aptitude
Metabolome
Drug Design
Therapeutics
Amyloid
Neurodegenerative Diseases
Proteomics
Dementia
Disease Progression
Animal Models
Biomarkers
Clinical Trials
Pathology
Health
Proteins

Keywords

  • Alzheimer's Disease
  • Animal models
  • Biomarkers
  • Cerebrospinal fluid
  • Metabolomics
  • Plasma

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine

Cite this

Recent advances in the application of metabolomics to Alzheimer's Disease. / Trushina, Eugenia; Mielke, Michelle M.

In: Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1842, No. 8, 2014, p. 1232-1239.

Research output: Contribution to journalArticle

Trushina, Eugenia ; Mielke, Michelle M. / Recent advances in the application of metabolomics to Alzheimer's Disease. In: Biochimica et Biophysica Acta - Molecular Basis of Disease. 2014 ; Vol. 1842, No. 8. pp. 1232-1239.
@article{160404e0f864458090f16a08e11b44ac,
title = "Recent advances in the application of metabolomics to Alzheimer's Disease",
abstract = "The pathophysiological changes associated with Alzheimer's Disease (AD) begin decades before the emergence of clinical symptoms. Understanding the early mechanisms associated with AD pathology is, therefore, especially important for identifying disease-modifying therapeutic targets. While the majority of AD clinical trials to date have focused on anti-amyloid-beta (Aβ) treatments, other therapeutic approaches may be necessary. The ability to monitor changes in cellular networks that include both Aβ and non-Aβ pathways is essential to advance our understanding of the etiopathogenesis of AD and subsequent development of cognitive symptoms and dementia. Metabolomics is a powerful tool that detects perturbations in the metabolome, a pool of metabolites that reflects changes downstream of genomic, transcriptomic and proteomic fluctuations, and represents an accurate biochemical profile of the organism in health and disease. The application of metabolomics could help to identify biomarkers for early AD diagnosis, to discover novel therapeutic targets, and to monitor therapeutic response and disease progression. Moreover, given the considerable parallel between mouse and human metabolism, the use of metabolomics provides ready translation of animal research into human studies for accelerated drug design. In this review, we will summarize current progress in the application of metabolomics in both animal models and in humans to further understanding of the mechanisms involved in AD pathogenesis. This article is part of a Special Issue entitled: Misfolded Proteins, Mitochondrial Dysfunction, and Neurodegenerative Diseases.",
keywords = "Alzheimer's Disease, Animal models, Biomarkers, Cerebrospinal fluid, Metabolomics, Plasma",
author = "Eugenia Trushina and Mielke, {Michelle M.}",
year = "2014",
doi = "10.1016/j.bbadis.2013.06.014",
language = "English (US)",
volume = "1842",
pages = "1232--1239",
journal = "Biochimica et Biophysica Acta - Molecular Basis of Disease",
issn = "0925-4439",
publisher = "Elsevier",
number = "8",

}

TY - JOUR

T1 - Recent advances in the application of metabolomics to Alzheimer's Disease

AU - Trushina, Eugenia

AU - Mielke, Michelle M.

PY - 2014

Y1 - 2014

N2 - The pathophysiological changes associated with Alzheimer's Disease (AD) begin decades before the emergence of clinical symptoms. Understanding the early mechanisms associated with AD pathology is, therefore, especially important for identifying disease-modifying therapeutic targets. While the majority of AD clinical trials to date have focused on anti-amyloid-beta (Aβ) treatments, other therapeutic approaches may be necessary. The ability to monitor changes in cellular networks that include both Aβ and non-Aβ pathways is essential to advance our understanding of the etiopathogenesis of AD and subsequent development of cognitive symptoms and dementia. Metabolomics is a powerful tool that detects perturbations in the metabolome, a pool of metabolites that reflects changes downstream of genomic, transcriptomic and proteomic fluctuations, and represents an accurate biochemical profile of the organism in health and disease. The application of metabolomics could help to identify biomarkers for early AD diagnosis, to discover novel therapeutic targets, and to monitor therapeutic response and disease progression. Moreover, given the considerable parallel between mouse and human metabolism, the use of metabolomics provides ready translation of animal research into human studies for accelerated drug design. In this review, we will summarize current progress in the application of metabolomics in both animal models and in humans to further understanding of the mechanisms involved in AD pathogenesis. This article is part of a Special Issue entitled: Misfolded Proteins, Mitochondrial Dysfunction, and Neurodegenerative Diseases.

AB - The pathophysiological changes associated with Alzheimer's Disease (AD) begin decades before the emergence of clinical symptoms. Understanding the early mechanisms associated with AD pathology is, therefore, especially important for identifying disease-modifying therapeutic targets. While the majority of AD clinical trials to date have focused on anti-amyloid-beta (Aβ) treatments, other therapeutic approaches may be necessary. The ability to monitor changes in cellular networks that include both Aβ and non-Aβ pathways is essential to advance our understanding of the etiopathogenesis of AD and subsequent development of cognitive symptoms and dementia. Metabolomics is a powerful tool that detects perturbations in the metabolome, a pool of metabolites that reflects changes downstream of genomic, transcriptomic and proteomic fluctuations, and represents an accurate biochemical profile of the organism in health and disease. The application of metabolomics could help to identify biomarkers for early AD diagnosis, to discover novel therapeutic targets, and to monitor therapeutic response and disease progression. Moreover, given the considerable parallel between mouse and human metabolism, the use of metabolomics provides ready translation of animal research into human studies for accelerated drug design. In this review, we will summarize current progress in the application of metabolomics in both animal models and in humans to further understanding of the mechanisms involved in AD pathogenesis. This article is part of a Special Issue entitled: Misfolded Proteins, Mitochondrial Dysfunction, and Neurodegenerative Diseases.

KW - Alzheimer's Disease

KW - Animal models

KW - Biomarkers

KW - Cerebrospinal fluid

KW - Metabolomics

KW - Plasma

UR - http://www.scopus.com/inward/record.url?scp=84903154904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903154904&partnerID=8YFLogxK

U2 - 10.1016/j.bbadis.2013.06.014

DO - 10.1016/j.bbadis.2013.06.014

M3 - Article

C2 - 23816564

AN - SCOPUS:84903154904

VL - 1842

SP - 1232

EP - 1239

JO - Biochimica et Biophysica Acta - Molecular Basis of Disease

JF - Biochimica et Biophysica Acta - Molecular Basis of Disease

SN - 0925-4439

IS - 8

ER -